Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biotechnology AssetsXMAD:BST -2.86%22 EV-to-EBITDA is 33.72 as of Jul. 21, 2026, which is 4859% above its 10-year median of 0.68. GuruFocus rates XMAD:BST with a GF Score™ of 22/100 and a GF Value™ of €0.30 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 398 Biotechnology companies, Biotechnology Assets ranks worse than 77.14% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biotechnology Assets's enterprise value is €18.72 Mil.
Biotechnology Assets's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.56 Mil. Therefore, Biotechnology Assets's EV-to-EBITDA for today is 33.72.
The historical rank and industry rank for Biotechnology Assets's EV-to-EBITDA or its related term are showing as below:
XMAD:BST'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -999.49 Med: 0.68 Max: 339.03
Current: 33.72
During the past 13 years, the highest EV-to-EBITDA of Biotechnology Assets was 339.03. The lowest was -999.49. And the median was 0.68.
XMAD:BST's EV-to-EBITDA is ranked worse than 77.14% of 398
companies
in the Biotechnology industry
Industry Median: 12.205
vs XMAD:BST: 33.72
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biotechnology Assets's PE Ratio (TTM) for today is calculated as:
Biotechnology Assets's share price for today is €0.204.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotechnology Assets's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.027.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biotechnology Assets's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:BST vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Biotechnology Assets's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's EV-to-EBITDA falls into.
Biotechnology Assets's current Enterprise Value is €18.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotechnology Assets's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets (XMAD:BST) has a EV-to-EBITDA of 33.72 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biotechnology Assets. This is 4859% above median its historical median of 0.68. According to the industry distribution chart, Biotechnology Assets ranks #307 out of 398 companies in the Biotechnology industry, placing it in the top 77.1%.
Is Biotechnology Assets' EV-to-EBITDA too high?
Biotechnology Assets' current EV-to-EBITDA of 33.72 is 4859% above median its 10-year median of 0.68. The Biotechnology industry median EV-to-EBITDA is 12.21. Biotechnology Assets' value of 33.72 is 176.3% above this industry median. Based on the distribution chart, Biotechnology Assets ranks #307 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biotechnology Assets has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #307 out of 398 companies for EV-to-EBITDA. This places Biotechnology Assets in the lower half of its industry. The industry median EV-to-EBITDA is 12.21. Biotechnology Assets' value of 33.72 is 176.3% above this benchmark. While the company's 10-year median is 0.68 vs. the industry median of 12.21, Biotechnology Assets has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.21, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotechnology Assets's current EV-to-EBITDA of 33.72 is 176.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biotechnology Assets. For the Biotechnology industry, the median EV-to-EBITDA is 12.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotechnology Assets's current EV-to-EBITDA is 33.72, which is 4859% above median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Possible Value Trap. The stock's GF Value™ is €0.30, compared to a current price of €0.20 — trading 32% below its estimated fair value. The current EV-to-EBITDA is 33.72, which is 4859% above median its 10-year median of 0.68 and 176.3% above the Biotechnology industry median of 12.21. Biotechnology Assets' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current EV-to-EBITDA is 33.72 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.20 is trading 32% below its estimated GF Value™ of €0.30.
GuruFocus considers Biotechnology Assets to be Possible Value Trap.
Key valuation signals for XMAD:BST:
EV-to-EBITDA: 33.72 (4859% above median its 10-year median of 0.68)
GF Value™: €0.30 vs. price of €0.20 (32% below fair value)
Industry Position: 176.3% above the Biotechnology median (#307 of 398)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
22GF Score
Get the complete analysis for XMAD:BST
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
